Evaluation of the efficiency and safety of imeglimin on insulin secretion ability and insulin sensitivity in the treatment of type 2 diabetes mellitus
Not Applicable
Recruiting
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000053150
- Lead Sponsor
- Department of Diabetes and Metabolism,Tohto Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) eGFR<30 2) Pregnancy or breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood glucose and IRI are set to be measured at baseline,3,6,9,12 months
- Secondary Outcome Measures
Name Time Method Body mass index (BMI),blood pressure,albumin creatinine ratio (ACR),lipid and liver function are set to be measured at baseline,3,6,9,12 months